Profiel
Trine Bartholdy formerly worked at Danmarks Eksport- og Investeringsfond, as Investment Director, NsGene A, as Director, Egalet Ltd., as Director, JenaValve Technology GmbH, as Director, Sunstone Capital A, as Investment Director from 2007 to 2011, and Forendo Pharma Oy, as Director.
Ms. Bartholdy received her graduate degree from Copenhagen Business School.
Eerdere bekende functies van Trine Bartholdy
Bedrijven | Functie | Einde |
---|---|---|
Sunstone Capital A/S
Sunstone Capital A/S Investment ManagersFinance Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors. | Director of Investments | 01-04-2011 |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Directeur/Bestuurslid | - |
JenaValve Technology GmbH
JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Directeur/Bestuurslid | - |
Egalet Ltd.
Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Directeur/Bestuurslid | - |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | Directeur/Bestuurslid | - |
Opleiding van Trine Bartholdy
Copenhagen Business School | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 6 |
---|---|
Danmarks Eksport- og Investeringsfond
Danmarks Eksport- og Investeringsfond Investment ManagersFinance Danmarks Eksport- og Investeringsfond (EIFO) is a venture capital subsidiary of Government of Denmark and founded in 1992. The firm is headquartered in Hellerup, Denmark. | Finance |
Sunstone Capital A/S
Sunstone Capital A/S Investment ManagersFinance Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors. | Finance |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | Health Technology |
Egalet Ltd.
Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Health Technology |
JenaValve Technology GmbH
JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Health Technology |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Health Technology |